Femodene Ed 0,03 mg/0,075 mg Coated tablets.
PDF Leaflet Revision Date: 20 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Oral contraception.
Dosage (summary)
One tablet daily for 28 days, starting on day 1 of the menstrual cycle.
Special Populations
- Paediatric patients
- Elderly patients
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; may reduce breast milk quantity and change composition during lactation.
Key Drug Interactions
- Enzyme inducers (e.g., phenytoin, rifampicin)
- CYP3A4 inhibitors (e.g., azole antifungals)
Contraindications
- Hypersensitivity
- Thromboembolic events
- Severe hepatic disease
- Undiagnosed vaginal bleeding
- Pregnancy
Common side effects
- Nausea
- Headache
- Depressed mood
- Breast tenderness
- Weight gain
Counselling Points
- Take at the same time daily
- Use barrier method if missed doses
- Report mood changes or severe abdominal pain
Serious warnings
- Increased risk of thromboembolism
- Monitor for migraine exacerbation
- Potential for liver tumors
Important Disclaimer
The Femodene Ed 0,03 mg/0,075 mg Coated tablets. professional information leaflet below is the property of Bayer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
